Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q1 2022 on May 3, 2022, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will release its financial results for Q1 2022 on May 3, 2022, before market opening. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET to discuss the results and business outlook. The event will be available for live audio streaming on the company’s investors' page. Nautilus is focused on advancing proteomics technology to enhance healthcare. For more information, visit www.nautilus.bio.
Positive
- Anticipation of Q1 2022 financial results may build investor interest.
- The company's focus on proteomics development positions it well for future growth.
Negative
- None.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -1.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Contacts
Investors:
InvestorRelations@nautilus.bio
Media:
Thermal for Nautilus Biotechnology
Kaustuva Das
Press@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.